Edmond DE Rothschild Holding S.A. Reduces Stock Holdings in Cencora, Inc. $COR

Edmond DE Rothschild Holding S.A. lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 28.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,537 shares of the company’s stock after selling 600 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Cencora were worth $461,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Artisan Partners Limited Partnership bought a new position in Cencora during the second quarter valued at $411,888,000. Invesco Ltd. boosted its stake in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the period. Vanguard Group Inc. grew its holdings in Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Cencora by 4,459.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after purchasing an additional 975,362 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on COR. Mizuho upped their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. TD Cowen increased their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wells Fargo & Company boosted their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Trading Down 1.6%

Shares of NYSE COR opened at $368.64 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The business has a fifty day simple moving average of $332.58 and a two-hundred day simple moving average of $306.37. The firm has a market cap of $71.47 billion, a PE ratio of 37.93, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is 30.19%.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 46,640 shares of company stock valued at $14,099,338. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.